A deep reinforcement learning platform for antibiotic discovery

Authors:
  • HCHanqun Cao
    Hanqun Cao
  • MTMarcelo D. T. Torres
    Marcelo D. T. Torres
  • JZJingjie Zhang
    Jingjie Zhang
  • ZGZijun Gao
    Zijun Gao
  • FWFang Wu
    Fang Wu
  • CGChunbin Gu
    Chunbin Gu
  • JLJure Leskovec
    Jure Leskovec
  • YCYejin Choi
    Yejin Choi
  • CFCesar de la Fuente-Nunez
    Cesar de la Fuente-Nunez
  • GCGuangyong Chen
    Guangyong Chen
  • PHPheng-Ann Heng
    Pheng-Ann Heng

Abstract
Antimicrobial resistance (AMR) is projected to cause up to 10 million deaths annually by 2050, underscoring the urgent need for new antibiotics. Here we present ApexAmphion, a deep-learning framework for de novo design of antibiotics that couples a 6.4-billion-parameter protein language model with reinforcement learning. The model is first fine-tuned on curated peptide data to capture antimicrobial sequence regularities, then optimised with proximal policy optimization against a composite reward that combines predictions from a learned minimum inhibitory concentration (MIC) classifier with differentiable physicochemical objectives. In vitro evaluation of 100 designed peptides showed low MIC values (nanomolar range in some cases) for all candidates (100% hit rate). Moreover, 99 our of 100 compounds exhibited broad-spectrum antimicrobial activity against at least two clinically relevant bacteria. The lead molecules killed bacteria primarily by potently targeting the cytoplasmic membrane. By unifying generation, scoring and multi-objective optimization with deep reinforcement learning in a single pipeline, our approach rapidly produces diverse, potent candidates, offering a scalable route to peptide antibiotics and a platform for iterative steering toward potency and developability within hours.
All Related Versions